| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 23 | 2024 | 66 | 4.700 |
Why?
|
| Flavonoids | 12 | 2021 | 20 | 4.400 |
Why?
|
| Glucuronosyltransferase | 21 | 2022 | 30 | 4.030 |
Why?
|
| Glucuronides | 16 | 2021 | 28 | 3.820 |
Why?
|
| Animals | 71 | 2024 | 1711 | 3.560 |
Why?
|
| Chromatography, High Pressure Liquid | 19 | 2020 | 44 | 2.800 |
Why?
|
| Chromatography, Liquid | 6 | 2024 | 37 | 2.120 |
Why?
|
| Diarrhea | 7 | 2024 | 23 | 2.100 |
Why?
|
| Liver | 14 | 2021 | 49 | 1.970 |
Why?
|
| Rats, Inbred F344 | 6 | 2024 | 21 | 1.970 |
Why?
|
| Rats | 22 | 2024 | 241 | 1.930 |
Why?
|
| Male | 44 | 2024 | 2491 | 1.840 |
Why?
|
| Mice | 32 | 2024 | 685 | 1.820 |
Why?
|
| Multidrug Resistance-Associated Proteins | 5 | 2021 | 8 | 1.810 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2021 | 6 | 1.760 |
Why?
|
| Mouth Neoplasms | 4 | 2023 | 8 | 1.710 |
Why?
|
| Humans | 49 | 2024 | 4936 | 1.660 |
Why?
|
| Sulfones | 3 | 2022 | 10 | 1.560 |
Why?
|
| Fluorescent Dyes | 3 | 2022 | 32 | 1.540 |
Why?
|
| Camptothecin | 4 | 2024 | 9 | 1.530 |
Why?
|
| Plant Extracts | 5 | 2020 | 15 | 1.500 |
Why?
|
| Microsomes, Liver | 10 | 2020 | 15 | 1.460 |
Why?
|
| Drugs, Chinese Herbal | 6 | 2023 | 12 | 1.420 |
Why?
|
| Lactones | 4 | 2022 | 10 | 1.360 |
Why?
|
| Neoplasm Proteins | 4 | 2021 | 17 | 1.310 |
Why?
|
| Phenols | 2 | 2021 | 13 | 1.250 |
Why?
|
| Polyphenols | 4 | 2018 | 8 | 1.240 |
Why?
|
| Dinoprostone | 2 | 2019 | 7 | 1.150 |
Why?
|
| Colon | 2 | 2019 | 7 | 1.150 |
Why?
|
| HeLa Cells | 4 | 2021 | 18 | 1.090 |
Why?
|
| Celecoxib | 2 | 2019 | 3 | 1.090 |
Why?
|
| Feces | 3 | 2024 | 26 | 1.080 |
Why?
|
| Rats, Wistar | 8 | 2021 | 31 | 1.010 |
Why?
|
| Intestinal Mucosa | 11 | 2024 | 26 | 1.000 |
Why?
|
| Gallic Acid | 2 | 2016 | 2 | 0.960 |
Why?
|
| Hydrolyzable Tannins | 2 | 2016 | 2 | 0.960 |
Why?
|
| Magnolia | 3 | 2020 | 4 | 0.930 |
Why?
|
| Glucosides | 4 | 2020 | 5 | 0.910 |
Why?
|
| Glucuronidase | 3 | 2022 | 7 | 0.900 |
Why?
|
| Pharmaceutical Preparations | 2 | 2024 | 12 | 0.900 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 225 | 0.890 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 318 | 0.870 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 69 | 0.870 |
Why?
|
| Cyclooxygenase 2 | 2 | 2021 | 7 | 0.860 |
Why?
|
| Biological Availability | 5 | 2021 | 14 | 0.850 |
Why?
|
| Intestine, Small | 3 | 2021 | 6 | 0.850 |
Why?
|
| ATP-Binding Cassette Transporters | 4 | 2018 | 10 | 0.850 |
Why?
|
| Developing Countries | 1 | 2024 | 3 | 0.830 |
Why?
|
| Sulfotransferases | 4 | 2017 | 4 | 0.830 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 11 | 0.810 |
Why?
|
| Portal Vein | 2 | 2020 | 2 | 0.810 |
Why?
|
| Caco-2 Cells | 12 | 2024 | 21 | 0.800 |
Why?
|
| Osteoarthritis | 1 | 2023 | 4 | 0.800 |
Why?
|
| Precision Medicine | 3 | 2017 | 10 | 0.790 |
Why?
|
| Metabolic Detoxication, Phase II | 3 | 2021 | 4 | 0.770 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2023 | 9 | 0.760 |
Why?
|
| Bile | 4 | 2020 | 7 | 0.750 |
Why?
|
| Colorectal Neoplasms | 2 | 2019 | 12 | 0.750 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2021 | 125 | 0.740 |
Why?
|
| Benzofurans | 3 | 2021 | 6 | 0.730 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 25 | 0.730 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 19 | 0.730 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2024 | 9 | 0.730 |
Why?
|
| Kinetics | 8 | 2017 | 80 | 0.710 |
Why?
|
| Bilirubin | 2 | 2021 | 4 | 0.700 |
Why?
|
| Phytochemicals | 1 | 2021 | 3 | 0.700 |
Why?
|
| Hepatobiliary Elimination | 3 | 2020 | 5 | 0.690 |
Why?
|
| Optical Imaging | 1 | 2021 | 17 | 0.680 |
Why?
|
| Cell Engineering | 1 | 2021 | 2 | 0.680 |
Why?
|
| Genistein | 1 | 2021 | 5 | 0.680 |
Why?
|
| Biocompatible Materials | 1 | 2021 | 21 | 0.670 |
Why?
|
| Carcinoma | 1 | 2020 | 3 | 0.650 |
Why?
|
| Apigenin | 1 | 2020 | 1 | 0.640 |
Why?
|
| Flavanones | 1 | 2020 | 2 | 0.640 |
Why?
|
| Neoplasms | 2 | 2021 | 90 | 0.640 |
Why?
|
| Hydroxyl Radical | 1 | 2020 | 3 | 0.640 |
Why?
|
| Serum Albumin, Bovine | 1 | 2020 | 20 | 0.630 |
Why?
|
| Molecular Structure | 6 | 2021 | 84 | 0.630 |
Why?
|
| Stilbenes | 2 | 2017 | 6 | 0.600 |
Why?
|
| Sensitivity and Specificity | 7 | 2017 | 126 | 0.580 |
Why?
|
| Mice, Knockout | 10 | 2019 | 140 | 0.570 |
Why?
|
| Hesperidin | 1 | 2018 | 1 | 0.570 |
Why?
|
| Intestines | 6 | 2021 | 15 | 0.560 |
Why?
|
| Macrophages | 1 | 2018 | 26 | 0.560 |
Why?
|
| Mice, Inbred C57BL | 8 | 2023 | 184 | 0.550 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 12 | 0.530 |
Why?
|
| Caffeic Acids | 1 | 2017 | 1 | 0.530 |
Why?
|
| Lactates | 1 | 2017 | 1 | 0.530 |
Why?
|
| Female | 17 | 2024 | 2523 | 0.510 |
Why?
|
| Linear Models | 7 | 2021 | 58 | 0.490 |
Why?
|
| Cholestasis | 1 | 2016 | 2 | 0.490 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2016 | 2 | 0.490 |
Why?
|
| Mangifera | 1 | 2015 | 1 | 0.480 |
Why?
|
| Seeds | 1 | 2015 | 4 | 0.480 |
Why?
|
| Hepatocytes | 3 | 2021 | 13 | 0.470 |
Why?
|
| Curcumin | 1 | 2015 | 10 | 0.470 |
Why?
|
| Diterpenes | 1 | 2015 | 3 | 0.460 |
Why?
|
| Alkaloids | 4 | 2021 | 9 | 0.460 |
Why?
|
| Ethoxzolamide | 1 | 2015 | 1 | 0.450 |
Why?
|
| Biomarkers | 4 | 2021 | 81 | 0.450 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 25 | 0.440 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2018 | 9 | 0.430 |
Why?
|
| Tissue Distribution | 7 | 2024 | 26 | 0.430 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 16 | 0.420 |
Why?
|
| Membrane Transport Proteins | 3 | 2018 | 12 | 0.410 |
Why?
|
| Flavones | 4 | 2017 | 5 | 0.400 |
Why?
|
| Administration, Oral | 4 | 2021 | 33 | 0.380 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 4 | 0.360 |
Why?
|
| Inflammation | 3 | 2023 | 57 | 0.360 |
Why?
|
| Lignans | 3 | 2020 | 5 | 0.350 |
Why?
|
| Biphenyl Compounds | 3 | 2020 | 7 | 0.350 |
Why?
|
| Raloxifene Hydrochloride | 2 | 2021 | 5 | 0.340 |
Why?
|
| Quinolizines | 3 | 2021 | 5 | 0.320 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 52 | 0.320 |
Why?
|
| RAW 264.7 Cells | 2 | 2021 | 4 | 0.310 |
Why?
|
| Intestinal Absorption | 4 | 2019 | 9 | 0.310 |
Why?
|
| Biological Assay | 3 | 2021 | 32 | 0.290 |
Why?
|
| Autophagy | 2 | 2021 | 30 | 0.280 |
Why?
|
| Glycosides | 3 | 2017 | 3 | 0.280 |
Why?
|
| Microsomes | 3 | 2018 | 5 | 0.280 |
Why?
|
| Dogs | 3 | 2017 | 15 | 0.270 |
Why?
|
| Kaempferols | 2 | 2018 | 3 | 0.270 |
Why?
|
| Plants, Medicinal | 3 | 2023 | 5 | 0.260 |
Why?
|
| Umbelliferones | 2 | 2019 | 3 | 0.260 |
Why?
|
| Isoflavones | 2 | 2017 | 3 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 9 | 0.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 9 | 0.240 |
Why?
|
| Inactivation, Metabolic | 2 | 2016 | 3 | 0.240 |
Why?
|
| Madin Darby Canine Kidney Cells | 2 | 2016 | 8 | 0.240 |
Why?
|
| Signal Transduction | 4 | 2021 | 216 | 0.240 |
Why?
|
| Quinolines | 3 | 2021 | 21 | 0.240 |
Why?
|
| Ginsenosides | 2 | 2016 | 2 | 0.230 |
Why?
|
| Perfusion | 3 | 2020 | 9 | 0.230 |
Why?
|
| Chemoprevention | 2 | 2023 | 3 | 0.230 |
Why?
|
| Cell Line | 4 | 2021 | 84 | 0.220 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2024 | 14 | 0.220 |
Why?
|
| Cryptosporidiosis | 1 | 2024 | 5 | 0.210 |
Why?
|
| Cryptosporidium parvum | 1 | 2024 | 6 | 0.210 |
Why?
|
| Glycosyltransferases | 1 | 2024 | 4 | 0.210 |
Why?
|
| Protein Kinases | 1 | 2024 | 17 | 0.210 |
Why?
|
| Global Health | 1 | 2024 | 3 | 0.210 |
Why?
|
| Prunella | 1 | 2023 | 1 | 0.210 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 2 | 0.210 |
Why?
|
| Pterocarpans | 2 | 2021 | 3 | 0.210 |
Why?
|
| Sulfates | 3 | 2021 | 6 | 0.210 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 51 | 0.200 |
Why?
|
| Poverty | 1 | 2024 | 22 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2018 | 115 | 0.200 |
Why?
|
| Injections, Intra-Articular | 1 | 2023 | 2 | 0.200 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 5 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 10 | 0.200 |
Why?
|
| Adrenergic Neurons | 1 | 2023 | 2 | 0.200 |
Why?
|
| Locus Coeruleus | 1 | 2023 | 4 | 0.200 |
Why?
|
| Cell Line, Tumor | 6 | 2020 | 160 | 0.190 |
Why?
|
| Limit of Detection | 3 | 2021 | 27 | 0.190 |
Why?
|
| Pain | 1 | 2023 | 41 | 0.190 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 4 | 0.190 |
Why?
|
| Biliary Tract | 2 | 2020 | 5 | 0.190 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2022 | 4 | 0.190 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2022 | 1 | 0.190 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 33 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 20 | 0.180 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2021 | 4 | 0.180 |
Why?
|
| Carcinogenesis | 1 | 2021 | 9 | 0.180 |
Why?
|
| Fenoldopam | 1 | 2021 | 2 | 0.180 |
Why?
|
| Kidney Tubules | 1 | 2021 | 5 | 0.170 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 7 | 0.170 |
Why?
|
| Healthy Volunteers | 2 | 2020 | 37 | 0.170 |
Why?
|
| Catechols | 2 | 2019 | 3 | 0.170 |
Why?
|
| Antiviral Agents | 2 | 2018 | 16 | 0.170 |
Why?
|
| Materials Testing | 1 | 2021 | 17 | 0.170 |
Why?
|
| Metabolic Flux Analysis | 1 | 2021 | 1 | 0.170 |
Why?
|
| Biosynthetic Pathways | 1 | 2021 | 3 | 0.170 |
Why?
|
| Particle Size | 1 | 2021 | 41 | 0.170 |
Why?
|
| Enzymes | 2 | 2018 | 4 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 55 | 0.170 |
Why?
|
| Enterohepatic Circulation | 1 | 2020 | 1 | 0.170 |
Why?
|
| Organic Anion Transporters | 1 | 2020 | 1 | 0.170 |
Why?
|
| Metabolome | 2 | 2018 | 4 | 0.170 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 1 | 0.170 |
Why?
|
| HEK293 Cells | 1 | 2020 | 30 | 0.160 |
Why?
|
| Microbiota | 1 | 2020 | 14 | 0.160 |
Why?
|
| Dietary Supplements | 1 | 2020 | 6 | 0.160 |
Why?
|
| Nod Signaling Adaptor Proteins | 1 | 2020 | 2 | 0.160 |
Why?
|
| Aminopyridines | 1 | 2020 | 5 | 0.160 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cattle | 1 | 2020 | 18 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2020 | 56 | 0.160 |
Why?
|
| Tartrates | 1 | 2019 | 1 | 0.160 |
Why?
|
| Herb-Drug Interactions | 1 | 2019 | 1 | 0.160 |
Why?
|
| Apoptosis | 2 | 2018 | 46 | 0.150 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 7 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 23 | 0.150 |
Why?
|
| Models, Molecular | 2 | 2019 | 82 | 0.150 |
Why?
|
| Oxygen | 2 | 2016 | 18 | 0.150 |
Why?
|
| Treatment Outcome | 1 | 2019 | 177 | 0.150 |
Why?
|
| Kidney | 2 | 2017 | 51 | 0.150 |
Why?
|
| Emtricitabine | 1 | 2018 | 1 | 0.140 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2018 | 1 | 0.140 |
Why?
|
| Organophosphates | 1 | 2018 | 2 | 0.140 |
Why?
|
| Adenine | 1 | 2018 | 3 | 0.140 |
Why?
|
| Blood Chemical Analysis | 2 | 2015 | 3 | 0.140 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 5 | 0.140 |
Why?
|
| Toxicity Tests | 1 | 2018 | 3 | 0.140 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 8 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 15 | 0.140 |
Why?
|
| NFATC Transcription Factors | 1 | 2018 | 12 | 0.140 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 26 | 0.140 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 12 | 0.140 |
Why?
|
| Diet | 1 | 2018 | 40 | 0.140 |
Why?
|
| Mice, Nude | 4 | 2020 | 19 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 26 | 0.140 |
Why?
|
| Benzylisoquinolines | 1 | 2017 | 1 | 0.140 |
Why?
|
| Melanthiaceae | 1 | 2017 | 1 | 0.130 |
Why?
|
| Isotope Labeling | 1 | 2017 | 3 | 0.130 |
Why?
|
| Models, Biological | 1 | 2018 | 124 | 0.130 |
Why?
|
| Benzaldehydes | 1 | 2017 | 1 | 0.130 |
Why?
|
| Salvia miltiorrhiza | 1 | 2017 | 1 | 0.130 |
Why?
|
| Depsides | 1 | 2017 | 1 | 0.130 |
Why?
|
| Cinnamates | 1 | 2017 | 3 | 0.130 |
Why?
|
| Enzyme Activation | 1 | 2017 | 13 | 0.130 |
Why?
|
| Pharmacokinetics | 1 | 2017 | 3 | 0.130 |
Why?
|
| Isotopes | 1 | 2017 | 1 | 0.130 |
Why?
|
| Luteolin | 1 | 2016 | 1 | 0.130 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2016 | 3 | 0.130 |
Why?
|
| Gene Expression | 1 | 2017 | 49 | 0.130 |
Why?
|
| Aging | 1 | 2018 | 109 | 0.130 |
Why?
|
| Adult | 3 | 2017 | 1567 | 0.130 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 1 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
|
| Histone Deacetylase 1 | 1 | 2016 | 2 | 0.120 |
Why?
|
| beta Catenin | 1 | 2016 | 7 | 0.120 |
Why?
|
| Swine, Miniature | 1 | 2016 | 4 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 15 | 0.120 |
Why?
|
| Rats, Gunn | 1 | 2016 | 1 | 0.120 |
Why?
|
| Isoenzymes | 4 | 2018 | 11 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 8 | 0.120 |
Why?
|
| Artemisinins | 1 | 2016 | 7 | 0.120 |
Why?
|
| Swine | 1 | 2016 | 50 | 0.120 |
Why?
|
| HIV Infections | 1 | 2018 | 104 | 0.120 |
Why?
|
| Sodium-Glucose Transporter 1 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Middle Aged | 2 | 2017 | 967 | 0.120 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cell Line, Transformed | 1 | 2015 | 6 | 0.120 |
Why?
|
| Protein Transport | 1 | 2015 | 30 | 0.120 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2015 | 1 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 96 | 0.120 |
Why?
|
| Quality Control | 1 | 2015 | 5 | 0.120 |
Why?
|
| Pregnenolone | 1 | 2015 | 1 | 0.110 |
Why?
|
| Panax | 1 | 2015 | 1 | 0.110 |
Why?
|
| Brain Chemistry | 1 | 2015 | 5 | 0.110 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 9 | 0.110 |
Why?
|
| Cobalt | 1 | 2015 | 11 | 0.110 |
Why?
|
| Area Under Curve | 3 | 2020 | 16 | 0.110 |
Why?
|
| Aged | 1 | 2017 | 703 | 0.100 |
Why?
|
| Uridine Diphosphate | 2 | 2024 | 5 | 0.100 |
Why?
|
| Mass Spectrometry | 3 | 2020 | 20 | 0.100 |
Why?
|
| Phytotherapy | 2 | 2023 | 5 | 0.080 |
Why?
|
| Crystallography, X-Ray | 2 | 2020 | 36 | 0.080 |
Why?
|
| Half-Life | 2 | 2021 | 9 | 0.080 |
Why?
|
| Reactive Oxygen Species | 2 | 2020 | 30 | 0.080 |
Why?
|
| Saponins | 2 | 2019 | 3 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2019 | 16 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 163 | 0.070 |
Why?
|
| Drug Stability | 2 | 2017 | 6 | 0.070 |
Why?
|
| Arylsulfotransferase | 2 | 2017 | 2 | 0.070 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 2 | 2019 | 3 | 0.070 |
Why?
|
| Sex Factors | 2 | 2018 | 76 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2018 | 68 | 0.060 |
Why?
|
| A549 Cells | 2 | 2016 | 3 | 0.060 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2016 | 5 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 21 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 29 | 0.060 |
Why?
|
| Glycosylation | 2 | 2015 | 10 | 0.060 |
Why?
|
| Permeability | 2 | 2015 | 14 | 0.060 |
Why?
|
| Antiprotozoal Agents | 1 | 2024 | 2 | 0.050 |
Why?
|
| Protozoan Proteins | 1 | 2024 | 4 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2024 | 6 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2024 | 3 | 0.050 |
Why?
|
| Cryptosporidium | 1 | 2024 | 4 | 0.050 |
Why?
|
| Plants | 1 | 2024 | 26 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 27 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2023 | 13 | 0.050 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2022 | 11 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 9 | 0.050 |
Why?
|
| Sirtuin 1 | 1 | 2022 | 1 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2022 | 5 | 0.050 |
Why?
|
| Prostate | 1 | 2022 | 9 | 0.050 |
Why?
|
| Cellular Senescence | 1 | 2022 | 14 | 0.050 |
Why?
|
| Luminescence | 1 | 2022 | 11 | 0.050 |
Why?
|
| Attention | 1 | 2023 | 66 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 87 | 0.040 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2021 | 4 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2021 | 16 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2021 | 9 | 0.040 |
Why?
|
| Glucuronates | 1 | 2021 | 2 | 0.040 |
Why?
|
| Digoxin | 1 | 2021 | 1 | 0.040 |
Why?
|
| Renal Reabsorption | 1 | 2021 | 1 | 0.040 |
Why?
|
| Piperidines | 1 | 2021 | 15 | 0.040 |
Why?
|
| Gilbert Disease | 1 | 2021 | 1 | 0.040 |
Why?
|
| Triazoles | 1 | 2021 | 5 | 0.040 |
Why?
|
| Protein Structure, Secondary | 1 | 2021 | 22 | 0.040 |
Why?
|
| Pyridones | 1 | 2021 | 8 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 65 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 23 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2021 | 3 | 0.040 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 4 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 47 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2021 | 19 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 32 | 0.040 |
Why?
|
| Lysosomes | 1 | 2021 | 21 | 0.040 |
Why?
|
| Esterases | 1 | 2020 | 5 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 10 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 44 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 66 | 0.040 |
Why?
|
| Mitochondria | 1 | 2020 | 20 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2019 | 6 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2019 | 9 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 17 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 13 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2019 | 43 | 0.040 |
Why?
|
| Fatty Alcohols | 1 | 2019 | 2 | 0.040 |
Why?
|
| Crystallization | 1 | 2019 | 83 | 0.040 |
Why?
|
| Diketopiperazines | 1 | 2019 | 2 | 0.040 |
Why?
|
| Propionates | 1 | 2019 | 3 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2019 | 5 | 0.040 |
Why?
|
| Monoterpenes | 1 | 2018 | 1 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 5 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 7 | 0.040 |
Why?
|
| Calcineurin | 1 | 2018 | 11 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 14 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 1 | 0.040 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2018 | 3 | 0.040 |
Why?
|
| Carboxylesterase | 1 | 2018 | 1 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2018 | 15 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 35 | 0.040 |
Why?
|
| Fatty Liver | 1 | 2018 | 7 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Models, Animal | 1 | 2018 | 24 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 115 | 0.030 |
Why?
|
| Equipment Design | 1 | 2018 | 68 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 40 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 58 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2018 | 111 | 0.030 |
Why?
|
| Liliaceae | 1 | 2017 | 1 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 6 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 4 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 6 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 3 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2017 | 26 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 1 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 2 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 6 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 4 | 0.030 |
Why?
|
| Histones | 1 | 2016 | 12 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 27 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 11 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 23 | 0.030 |
Why?
|
| Antimalarials | 1 | 2016 | 17 | 0.030 |
Why?
|
| Glucosylceramidase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Enterocytes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 27 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 9 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 14 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2015 | 2 | 0.030 |
Why?
|
| Coumarins | 1 | 2015 | 3 | 0.030 |
Why?
|
| Benzoxepins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Limonins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Triterpenes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Lamiaceae | 1 | 2015 | 1 | 0.030 |
Why?
|
| Isomerism | 1 | 2015 | 6 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2015 | 29 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 161 | 0.030 |
Why?
|
| Algorithms | 1 | 2015 | 241 | 0.020 |
Why?
|